Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2028

Conditions

Non-small Cell Lung Cancer (NSCLC)EGFR Mutation-Positive Lung CancerBrain MetastasesLeptomeningeal MetastasesIntracranial Tumor Progression

Interventions

DRUG

The treatment regimen is Furmonertinib combined with Bevacizumab.

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Li-kun Chen

OTHER